CYP2C9 variants linked to clinical events in VTE

<i>CYP2C9</i> variants linked to clinical events in VTE

(HealthDay)—For elderly patients treated with vitamin K antagonists for venous thromboembolism (VTE), CYP2C9 variants are associated with any clinical event, according to a study published online Aug. 22 in the Journal of Thrombosis and Haemostasis.

Michael Nagler, M.D., from Bern University Hospital in Switzerland, and colleagues examined the correlation between CYP2C9/VKORC1 variants and long-term clinical outcomes among 774 treated with vitamin K antagonists for VTE.

Overall, 78 percent of the had a CYP2C9 or VKORC1 variant. The researchers found that 43.2 percent of patients had any clinical event, 15.4 percent died, 12.9 and 21.6 percent had major and non-major bleeding, respectively, and 12.9 percent had recurrent VTE. After adjustment there was a correlation for CYP2C9 variants with any clinical event (hazard ratio, 1.34; 95 percent confidence interval, 1.08 to 1.66), death (hazard ratio, 1.74; 95 percent confidence interval, 1.19 to 2.52), and clinically relevant non-major bleeding (subhazard ratio, 1.39; 95 percent confidence interval, 1.02 to 1.89), but not with major bleeding (subhazard ratio, 1.03; 95 percent confidence interval, 0.69 to 1.55) or recurrent VTE (subhazard ratio, 0.95; 95 percent interval, 0.62 to 1.44). Slightly lower anticoagulation quality was seen for patients with genetic variants.

"CYP2C9 was associated with long-term overall mortality and non-major bleeding," the authors write. "While genetic variants were associated with a slightly lower anticoagulation quality, there was no relationship between genetic variants and major bleeding or VTE recurrence."

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2017 HealthDay. All rights reserved.

Citation: CYP2C9 variants linked to clinical events in VTE (2017, September 5) retrieved 5 February 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Stem cell factor tied to reduced risk of cardiac events, death


Feedback to editors